Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial

Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T20:25:00.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification related to the safety and tolerability evaluation of RGX-314 gene therapy for neovascular age-related macular degeneration (nAMD).
    Difference
    0.1%
    Check dated 2024-06-06T14:17:27.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to include detailed eligibility criteria for study participants, specifying age, diagnosis, and prior treatments required for inclusion. This change provides more specific information about the health conditions and prior treatments needed for participation in the clinical study.
    Difference
    23%
    Check dated 2024-05-22T19:36:38.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Summary
    The value 'Go to the classic website Go to the classic website 5 2' on the webpage has been updated to 'type of intervention Site Map 6 0'. This change likely indicates a modification related to the type of intervention, possibly concerning medical and healthcare-related publications and documentation.
    Difference
    1%
    Check dated 2024-05-01T17:59:22.000Z thumbnail image

Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.